Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.

Try Elite for Free

New Feature: All Finviz Members Now Get Real-Time Earnings Data

AgomAb Therapeutics NV

Contributing Author

Recent Articles by AgomAb Therapeutics NV

Oct-01	Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease AGMB -22.07% GlobeNewswire
Sep-14	Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study AGMB -5.97% GlobeNewswire
Sep-11	Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors AGMB -6.31% GlobeNewswire
Sep-03	Agomab to Participate in Upcoming Investor Conferences AGMB +8.57% AGMB +6.41% GlobeNewswire
Aug-10	Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors AGMB GlobeNewswire
Aug-06	Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook AGMB -5.73% AGMB +7.41% GlobeNewswire
Jun-23	Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn's Disease AGMB AGMB +6.20% GlobeNewswire
May-27	Agomab Announces Results of Annual General Meeting AGMB +5.61% GlobeNewswire
May-14	Agomab to Participate in Upcoming Conferences AGMB GlobeNewswire
Apr-23	Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook AGMB GlobeNewswire
Mar-26	Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis AGMB -7.70% GlobeNewswire
Feb-09	Agomab Announces Closing of Initial Public Offering AGMB +6.55% GlobeNewswire
Feb-05	Agomab Announces Pricing of Initial Public Offering AGMB GlobeNewswire

Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)